SAN FRANCISCO, CA — GigaGen CEO David Johnson is excited to announce that Steve Chamow, PhD, has joined GigaGen as manufacturing lead. Dr. Chamow will help GigaGen surmount the manufacturing challenges inherent in the development of a recombinant version of IVIG.

 

Dr. Chamow has more than 20 years of experience in biopharmaceutical product development. A principal consultant, he helps biotechnology companies to develop CMC strategies for products in development and lifecycle strategies for marketed products. Over his career, he contributed to the development of three marketed products (Avastin, Natrecor, Vectibix).

 

Previously, he served as Senior Vice President, CMC, at Intradigm Corporation, a private biopharmaceutical company focused on developing RNAi therapeutics (acquired by Silence Therapeutics). Prior to Intradigm, Dr. Chamow was Vice President, Process Sciences, at Genitope Corporation and at Abgenix, Inc., (acquired by Amgen) where he built the company’s process sciences department and co-led the design and construction of Abgenix’ award-winning mammalian cell production facility in Fremont, CA.

 

Before Abgenix, he served as Director of Biopharmaceutical Development at Scios, Inc., (acquired by J&J), and as a scientist and senior scientist in process development at Genentech, Inc. Dr. Chamow was educated at the University of California (UC Santa Cruz, B.A. in biology; UC Davis, Ph.D. in biochemistry), and completed postdoctoral training at the National Institutes of Health. Dr. Chamow is author or co-author of more than 45 scientific publications and patents and co-editor of a 1999 book entitled Antibody Fusion Proteins.

GigaGen Inc., a biopharmaceutical company developing a pipeline of novel antibody therapies, has published a study in collaboration with authors from a leading antibody drug developer that sheds new light on methods for increasing the success of antibody discovery in mice. The study, “A natively paired antibody library yields drug leads with higher sensitivity and specificity than a randomly paired antibody library,” is available online and will appear in the upcoming issue of the peer-reviewed scientific journal mAbs.

Read the full press release.

SOUTH SAN FRANCISCO, Calif., April 15, 2021 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research, titled, “Generation of recombinant hyperimmune globulins from diverse B cell repertoires,” in the peer-reviewed journal Nature Biotechnology. The data describes GigaGen’s proprietary technology for the production of a new class of antibody drug, “recombinant hyperimmune globulins,” which include its novel COVID-19 therapy, GIGA-2050. This program recently received an Investigational New Drug (IND) approval by the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial. A previous version of the data was made available through bioRxiv.

Read the full press release.

Antibodies have been used since the late 1980s as therapies to treat serious diseases, and demand is soaring to new heights today. However, conventional antibody drug discovery technologies are labor-intensive and slow. Pharmaceutical companies select drug candidates from just a small fraction of the antibodies that exist in a natural immune repertoire and have limited information on which candidates are the most promising. Additionally, identification and selection of drug targets remain an arduous process because conventional approaches to studying the immune system are not comprehensive. GigaGen Inc., based in South San Francisco, CA, has developed a unique insight into immune dysregulation through a proprietary technology known as Surge – a platform that quickly characterizes every cell in complex immune systems so that natural immune repertoires can be translated into medical treatments. The technology powers selection of drug targets, identification of drug candidates, and preclinical assessment of efficacy. GigaGen is using their insight into how the immune system functions to discover and develop drugs that solve disorders of immune dysregulation, including cancer and immune deficiency.

Read the full story.

Antibodies from blood donated by people who recovered from the illness and hyper-immunoglobulins are becoming treatments of choice for COVID-19, with recombinant polyclonal antibody approaches to follow.

GigaGen, which is backed by Grifols, is a more recent arrival, and its cell-based recombinant polyclonal immunoglobulin production system is at an earlier stage of development. It involves capturing on a microfluidics platform the complete B-cell populations of five to ten people who have recovered COVID-19 and mounted a robust immune response to the virus. The associated antibody-encoding genes are then transferred into a mammalian cell line.

Read the full story.

Big Picture, Big Rewards – David Johnson, Ph.D., locks up his bicycle after a harrowing ride navigating hills and traffic to make his way to South San Francisco, Calif., the birthplace of biotechnology. It’s how he gets to and from work at GigaGen, a company he founded in 2010 to translate his research in single cell genomics into novel therapies for patients in need.

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of preclinical data validating its Surge™ discovery platform to rapidly interrogate and screen mouse and human antibody repertoires. The findings appear in two separate studies published online in the peer-reviewed scientific journal mAbs and will be available in print in the upcoming issue.

Read the full press release.